Physician profile
Mazdak Momeni
NPI 1275865917
$21,185.85
in general payments reported to CMS, 2019-2025
13 companies · $13K in 2025
The $13K reported for 2025 was more than what 92% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2021: $213 · 2022: $2,736 · 2023: $275 · 2024: $4,735 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $1,335 · Travel and Lodging: $929 · Education: $64.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,790.00 |
| Food and Beverage | $1,334.68 |
| Travel and Lodging | $929.07 |
| Education | $64.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17,092.74 | 2023-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals Lp | $2,864.17 | 2021-2022 | |
| Glaxosmithkline, LLC. | $172.24 | 2025 | Jemperli |
| Verastem, INC. | $153.12 | 2025 | Avmapki Fakzynja Co-Pack |
| Intuitive Surgical, INC. | $133.55 | 2023 | |
| Abbvie INC. | $124.99 | 2024 | |
| Dysis Medical, INC. | $124.27 | 2023 | Dysis View, Dysis V3 Digital Coploscope, Dysis Ultra 2.0 |
| Lilly USA, LLC | $123.98 | 2024 | Verzenio |
| Tesaro, INC. | $118.43 | 2019 | |
| Fennec Pharmaceuticals, INC. | $95.75 | 2025 | Fyarro |
| Myriad Genetic Laboratories, INC. | $85.00 | 2021 | |
| Corcept Therapeutics | $81.59 | 2025 | Korlym |
| Monaghan Medical Corporation | $16.02 | 2024 | Aeroeclipse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazdak Momeni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.